Study identifies patients with obesity most likely to benefit from GLP-1-based treatment

Why do some people lose substantial weight with GLP-1-based medications while others see more modest results?

A Mayo Clinic study offers a potential answer by identifying a distinct biological subtype of obesity that responds especially well to tirzepatide, a medication that mimics two naturally occurring hormones involved in appetite and blood sugar regulation, moving the field closer to precision medicine for obesity. ...